QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
Log in
NASDAQ:SELB

Selecta Biosciences Stock Forecast, Price & News

$3.25
+0.06 (+1.88 %)
(As of 11/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.14
Now: $3.25
$3.30
50-Day Range
$1.64
MA: $2.76
$3.36
52-Week Range
$1.32
Now: $3.25
$4.83
Volume1.64 million shs
Average Volume1.81 million shs
Market Capitalization$351.10 million
P/E RatioN/A
Dividend YieldN/A
Beta1.29
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that has completed Phase II clinical trials for the treatment of chronic refractory gout. It also engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; BIND Therapeutics, Inc.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.
Read More
Selecta Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.72 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SELB
CUSIPN/A
Phone617-923-1400
Employees39

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.68 million
Book Value$0.10 per share

Profitability

Net Income$-55,350,000.00

Miscellaneous

Market Cap$351.10 million
Next Earnings Date3/11/2021 (Estimated)
OptionableOptionable
$3.25
+0.06 (+1.88 %)
(As of 11/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SELB News and Ratings via Email

Sign-up to receive the latest news and ratings for SELB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Selecta Biosciences (NASDAQ:SELB) Frequently Asked Questions

How has Selecta Biosciences' stock been impacted by COVID-19?

Selecta Biosciences' stock was trading at $3.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SELB shares have increased by 5.2% and is now trading at $3.25.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Selecta Biosciences?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Selecta Biosciences
.

What stocks does MarketBeat like better than Selecta Biosciences?

Wall Street analysts have given Selecta Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Selecta Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Selecta Biosciences' next earnings date?

Selecta Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Selecta Biosciences
.

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences, Inc. (NASDAQ:SELB) released its quarterly earnings data on Thursday, November, 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.12) by $0.03. The firm had revenue of $4.65 million for the quarter, compared to analysts' expectations of $3.75 million.
View Selecta Biosciences' earnings history
.

What price target have analysts set for SELB?

7 brokerages have issued 12-month target prices for Selecta Biosciences' shares. Their forecasts range from $2.50 to $13.00. On average, they expect Selecta Biosciences' share price to reach $6.75 in the next twelve months. This suggests a possible upside of 107.7% from the stock's current price.
View analysts' price targets for Selecta Biosciences
.

Are investors shorting Selecta Biosciences?

Selecta Biosciences saw a increase in short interest in the month of October. As of October 30th, there was short interest totaling 10,580,000 shares, an increase of 18.2% from the October 15th total of 8,950,000 shares. Based on an average daily trading volume, of 2,680,000 shares, the short-interest ratio is presently 3.9 days.
View Selecta Biosciences' Short Interest
.

Who are some of Selecta Biosciences' key competitors?

What other stocks do shareholders of Selecta Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and TherapeuticsMD (TXMD).

Who are Selecta Biosciences' key executives?

Selecta Biosciences' management team includes the following people:
  • Dr. Carsten Brunn, CEO, Pres & Director (Age 49, Pay $942.52k)
  • Dr. Ulrich H. von Andrian-Werburg M.D., Ph.D., Co-Founder and Co-Chair of the Scientific Advisory Board
  • Mr. Bradford D. Dahms, CFO, Principal Financial Officer & Principal Accounting Officer (Age 32)
  • Dr. Lloyd Johnston, COO and Sr. VP of R&D (Age 52)
  • Dr. Takashi Kei Kishimoto, Chief Scientific Officer (Age 60)
  • Dr. Horacio Plotkin, Head of Clinical Devel. (Age 55)
  • Dr. Peter G. Traber, Chief Medical Officer (Age 65)
  • Ms. Ann K. Donohue, Controller

When did Selecta Biosciences IPO?

(SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

What is Selecta Biosciences' stock symbol?

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

Who are Selecta Biosciences' major shareholders?

Selecta Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Mangrove Partners (5.36%), BlackRock Inc. (4.12%), Wasatch Advisors Inc. (1.93%), State Street Corp (1.11%), Vivo Capital LLC (0.88%) and Point72 Asset Management L.P. (0.37%). Company insiders that own Selecta Biosciences stock include Amir Nashat, Carsten Brunn, Timothy A Springer and Timothy C Barabe.
View institutional ownership trends for Selecta Biosciences
.

Which institutional investors are selling Selecta Biosciences stock?

SELB stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Mangrove Partners, Point72 Asset Management L.P., Wasatch Advisors Inc., Jane Street Group LLC, Morgan Stanley, Arrowstreet Capital Limited Partnership, and Virtus ETF Advisers LLC.
View insider buying and selling activity for Selecta Biosciences
.

Which institutional investors are buying Selecta Biosciences stock?

SELB stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., AQR Capital Management LLC, JPMorgan Chase & Co., State Street Corp, Wells Fargo & Company MN, Squarepoint Ops LLC, Charles Schwab Investment Management Inc., and Verdence Capital Advisors LLC. Company insiders that have bought Selecta Biosciences stock in the last two years include Amir Nashat, Timothy A Springer, and Timothy C Barabe.
View insider buying and selling activity for Selecta Biosciences
.

How do I buy shares of Selecta Biosciences?

Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Selecta Biosciences' stock price today?

One share of SELB stock can currently be purchased for approximately $3.25.

How big of a company is Selecta Biosciences?

Selecta Biosciences has a market capitalization of $351.10 million and generates $6.68 million in revenue each year. The company earns $-55,350,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. Selecta Biosciences employs 39 workers across the globe.

What is Selecta Biosciences' official website?

The official website for Selecta Biosciences is selectabio.com.

How can I contact Selecta Biosciences?

Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The company can be reached via phone at 617-923-1400 or via email at [email protected]

This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.